Are Surrogate End Points in Drug-Eluting Stent Trials Reliable?

5-lipoxygenase gene disruption reduces amyloidpathology in a mouse model of Alzheimer’s disease. FASEB J 2008;22:1169 –78. 6. Manev R, Imbesi M, Uz T, Dzitoyeva S, Dimitrijevic N, Manev H. Effects of 5-lipoxygenase inhibitors MK-886 and caffeic acid in a model of forced swimming in wild-type and 5-lipoxygenase– deficient mice. Program 711.4/BB17. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. Available at: http://www. abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey {B531E434-A1EE-476C-9071-52AC68106587}&SKey {531A911D5233-4F6D-99FB-928B3456C2F8}&MKey {FF8B70E5-B7F9-4D07A58A-C1068FDE9D25}&AKey {3A7DC0B9-D787-44AA-BD08FA7BB2FE9004}. Accessed March 27, 2008. 7. Stewart JC, Janicki DL, Muldoon MF, Sutton-Tyrrell K, Kamarck TW. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch Gen Psychiatry 2007;64:225–33.

[1]  T. Wisniewski,et al.  5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  S. Reis,et al.  Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. , 2007, Journal of the American College of Cardiology.

[3]  A. Colombo,et al.  Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. , 2007, Journal of the American College of Cardiology.

[4]  A. Colombo,et al.  Angiographic analysis of pattern of late luminal loss in sirolimus- and paclitaxel-eluting stents. , 2007, The American journal of cardiology.

[5]  T. Kamarck,et al.  Negative emotions and 3-year progression of subclinical atherosclerosis. , 2007, Archives of general psychiatry.

[6]  G. Stone,et al.  Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.

[7]  A. Lusis,et al.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004, The New England journal of medicine.

[8]  M. Irwin.  Psychoneuroimmunology of Depression: Clinical Implications , 2002, Brain, Behavior, and Immunity.

[9]  A. Kastrati,et al.  Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. , 1997, Circulation.

[10]  KurtUlm,et al.  Bimodal Distribution of Angiographic Measures of Restenosis Six Months After Coronary Stent Placement , 1997 .

[11]  S. Pocock,et al.  Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. , 2008, Journal of the American College of Cardiology.

[12]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[13]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[14]  A. Hofman,et al.  Inflammatory proteins and depression in the elderly. , 2003, Epidemiology.